Quartel Adrian W 4

4 · ZEVRA THERAPEUTICS, INC. · Filed Feb 2, 2026

AI-generated summary of this filing

Updated Feb 2, 2026

Zevra Therapeutics (ZVRA) CMO Adrian W. Quartel Sells Shares

What Happened

Adrian W. Quartel, Chief Medical Officer of Zevra Therapeutics (ZVRA), reported several equity transactions around Jan 29–30, 2026. The headline item: he sold 4,533 shares in an open‑market transaction at a weighted average price of $8.83 for total proceeds of $40,036.
The filing also shows equity awards and derivative activity: grants of 37,500 restricted stock units (RSUs) and 75,000 stock options on Jan 29, 2026, and the vesting/settlement/exercise of 11,333 derivative shares on Jan 30 (one‑third of an award settled per footnote).

Key Details

Transaction dates: grants recorded 2026-01-29; vest/settlement and sale executed 2026-01-30.
Sale price: weighted average $8.83 (individual trades ranged $8.62–$9.04). Proceeds reported: $40,036. (Reporting person offered to provide breakdown of individual trade prices/quantities on request per the filing.)
Grants: 37,500 RSUs (F1/F4/F6) and 75,000 stock option grant (F5). Per footnotes, one‑third of the RSUs vested and settled on Jan 30, 2026; remaining RSUs vest in equal annual installments thereafter subject to continued service. The option vests in four equal annual installments beginning one year after grant.
10b5‑1 plan: filing notes a 10b5‑1 trading plan adoption date of 3/26/2025 (F2), indicating the sale may have been executed under a pre‑arranged plan.
Shares owned after the transactions: not specified in this Form 4 filing.
Timeliness: Form filed 2026-02-02 for transactions on Jan 29–30, 2026; the filing does not indicate a late filing.

Context

This filing combines routine equity compensation activity (RSU grants, an option grant, vesting/settlement) with a small open‑market sale. Sales executed under a 10b5‑1 plan are typically pre‑arranged and routine; the sale here was modest (~$40k) relative to the size of the grants.
For derivative items: the filing lists exercises/settlements of derivative awards (treated as conversions/vestings), and some of the shares that vested/settled were sold in the open market. The filing is factual; it does not state motivations.

Form 4

Period: 2026-01-29

Chief Medical Officer

Transactions

Exercise/Conversion
Common Stock
[F1]
2026-01-30+11,333→ 14,256 total
Sale
Common Stock
[F2][F3]
2026-01-30$8.83/sh−4,533$40,036→ 9,723 total
Award
Restricted Stock Unit
[F1][F4]
2026-01-29+37,500→ 37,500 total
→ Common Stock (37,500 underlying)
Award
Stock Option (right to buy)
[F5]
2026-01-29+75,000→ 75,000 total
Exercise: $8.86Exp: 2036-01-28→ Common Stock (75,000 underlying)
Exercise/Conversion
Restricted Stock Unit
[F1][F6]
2026-01-30−11,333→ 22,667 total
→ Common Stock (11,333 underlying)

Footnotes (6)

[F1]Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
[F2]Adoption date of referenced 10b5-1(c) plan is: 3/26/2025.
[F3]This transaction was executed in multiple trades at prices ranging from $8.62 to $9.04. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer or any security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
[F4]The restricted stock units will vest and settle as to one third of the restricted stock units on January 29, 2027, and the remaining two thirds of the restricted stock units will vest and settle in equal annual installments thereafter, subject in each case to the Reporting Person's continued service through such vesting date.
[F5]Grant to the Reporting Person of a stock option under the Issuer's Amended and Restated 2014 Equity Incentive Plan. The option will vest and become exercisable in four equal annual installments beginning on the first anniversary of the grant date, subject to the Reporting Person's continued service on such vesting date.
[F6]One third of the restricted stock units vested and settled on January 30, 2026. The remaining two thirds of the restricted stock units will vest and settle in equal annual installment thereafter, subject in each case to the Reporting Person's continued service through such vesting date.

Signature

/s/ Timothy J. Sangiovanni, Attorney-in-Fact for Adrian W. Quartel|2026-02-02

1 file